Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma [PDF]
World Journal of Surgical Oncology, 2013 Background Matrix metalloproteinases (MMPs) are one of the major classes of proteolytic enzymes involved in tumor invasion and metastasis and are inhibited by naturally occurring tissue inhibitors of metalloproteinases (TIMPs).
Qiao Zhen-kui +4 more
doaj +2 more sources
MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES DURING PREGNANCY AND DELIVERY [PDF]
Acta Biomedica Scientifica, 2012 Matrix metalloproteinases are main proteolytic enzymes breaking down most components of extracellular matrix of various tissues. In the review shows role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during implantation,
Yu. V. Korenovsky +6 more
doaj +1 more source
Modulation of plasma matrix metalloproteinase 9 and its inhibitors by vitamin D. [PDF]
, 2012 PhDMatrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are upregulated in a variety of diseases. Hypothesis: As TIMP-1 levels are elevated in liver fibrosis, might a similar process occur in essential hypertension driven left ...
Timms, Peter McLean
core +4 more sources
Role of matrix metalloproteinases in diabetic foot ulcers: Potential therapeutic targets
Frontiers in Pharmacology, 2022 Diabetic foot ulcers (DFUs) are pathological states of tissue destruction of the foot or lower extremity in diabetic patients and are one of the serious chronic complications of diabetes mellitus.
Kang Fu +11 more
doaj +1 more source
Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions [PDF]
European Respiratory Journal, 2005 The aim of this study was to assess the expression of several metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in exudative pleural effusions, and their relationship with inflammatory and fibrinolytic mediators in parapneumonic effusions.The study included 51 parapneumonic effusions (30 empyema or complicated parapneumonic,
D, Iglesias +9 more
openaire +2 more sources
Tissue inhibitors of metalloproteinases (TIMPs) modulate platelet ADAM10 activity
Platelets, 2023 Platelet-specific collagen receptor glycoprotein (GP)VI is stable on the surface of circulating platelets but undergoes ectodomain cleavage on activated platelets.
Christine Shu Mei Lee +5 more
doaj +1 more source
Correlation of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinase Expression in Ileal Carcinoids, Lymph Nodes and Liver Metastasis with Prognosis and Survival [PDF]
, 2009 Purpose: Ileal carcinoids are gut epithelial tumors originating from serotonin-containing enterochromaffin (EC) cells. Therapeutic options for effectively inhibiting the growth and spread of metastatic carcinoids are still limited.
Braun, Thomas +11 more
core +2 more sources
Tissue inhibitors of metalloproteinases [PDF]
Genome Biology, 2011 Orchestration of the growth and remodeling of tissues and responses of cells to their extracellular environment is mediated by metalloproteinases of the Metzincin clan. This group of proteins comprises several families of endopeptidases in which a zinc atom is liganded at the catalytic site to three histidine residues and an invariant methionine ...
openaire +2 more sources
Exogenously added GPI-anchored tissue inhibitor of matrix metal loproteinase-1 (TIMP-1) displays enhanced and novel biological activities [PDF]
, 2004 The family of tissue inhibitors of metalloproteinases (TIMPs) exhibits diverse physiological/biological functions including the inhibition of active matrix metalloproteinases, regulation of proMMP activation, cell growth, and the modulation of ...
P.J. Nelson +9 more
core +1 more source
Serum levels of matrix metalloproteinases-2 and-9 and their tissue inhibitors in inflammatory neuromuscular disorders [PDF]
, 2006 We monitored serum levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) before and during intravenously applied immunoglobulin (IVIG) therapy in 33 patients with chronic immune-mediated neuropathies and myopathies and 15 ...
Mueller-Felber, W. +3 more
core +1 more source